Eine neue Medikamentenkombination zur Behandlung von fortgeschrittenem wiederkehrendem Prostatakrebs hat in einer Langzeitstudie bemerkenswerte Ergebnisse gezeigt und das Sterberisiko nach acht Jahren um 40,3 % gesenkt. Darüber hinaus sind die medikamentösen Behandlungen bereits für die alleinige Anwendung zugelassen.

I’ve linked to the news release in the post above. In this comment, for those interested, here’s the link to the peer reviewed journal article:

https://www.nejm.org/doi/10.1056/NEJMoa2510310

From the linked article:

**A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What’s more, the drug treatments are already approved for use on their own.**

Up to 40% of men who undergo radiation or surgery for prostate cancer will see it return and be more difficult to treat in the same way. In this new study featuring more than 1,000 participants at 244 sites in 17 countries, patients received either enzalutamide plus leuprolide (the combination group), leuprolide (the leuprolide-alone group), or enzalutamide monotherapy (the monotherapy group). While the drugs on their own showed no meaningful significance in enhanced survival rates, when they were combined they lowered the risk of death by 40.3% after an average follow-up of 94 months.

The research was published in The New England Journal of Medicine.